Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OLMA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Palazestrant (OP-1250) | Breast Cancer | Phase 3 · NCT06016738 | Active not recruiting |
| Atirmociclib | Metastatic Breast Cancer | Phase 1 · NCT05508906 | Active not recruiting |
| KAT6 Inhibitor OP-3136 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Phase 1 · NCT06784193 | Recruiting |
Also used in these trials (approved or third-party drugs, not OLMA's own candidates): Anastrozole, Exemestane, Fulvestrant, Letrozole, Ribociclib, Alpelisib, Everolimus, Palbociclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OLMA holds $413.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $46.5M/quarter from operations, an estimated runway of 26.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 54 · Elevated
As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OLMA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 12,075,062 | 13.78% | 2026-06-30 |
| BVF PARTNERS L P/IL Director · +499,018 options |
Insider | 8,939,731 | 10.20% | 2026-10-14 |
| Bain Capital Life Sciences Opportunities | 5%+ holder (13G) | 7,473,238 | 8.53% | 2026-03-31 |
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 6,318,050 | 7.21% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 6,244,212 | 7.13% | 2026-06-30 |
| Siren, L.L.C. | Institution (13F) | 4,856,949 | 5.54% | 2026-09-30 |
| Raymond Debbane | 5%+ holder (13G) | 4,461,949 | 5.09% | 2026-03-16 |
| State Street Corporation | Institution (13F) | 3,847,478 | 4.39% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,513,193 | 4.01% | 2026-09-30 |
| Cyrus Harmon Director · +29,500 options |
Insider | 819,798 | 0.94% | 2026-07-23 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF · +406,250 options |
Insider | 555,592 | 0.63% | 2026-01-12 |
| Andrew Rappaport Director · +29,500 options |
Insider | 385,965 | 0.44% | 2025-11-21 |
Share count 87,606,263 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-01 filed 2026-09-02 |
O'Byrne Jason |
Option award (A) | 650,000 | – | – |
| 2026-07-24 filed 2026-07-27 |
Harmon Cyrus |
Sale (S) | 12,500 | $11.71 | 702,770 |
| 2026-07-23 filed 2026-07-27 |
Harmon Cyrus |
Sale (S) | 12,500 | $11.58 | 715,270 |
| 2026-06-18 filed 2026-06-23 |
BUTITTA CYNTHIA M |
Option award (A) | 29,500 | – | – |
| 2026-06-18 filed 2026-06-23 |
BIOTECHNOLOGY VALUE FUND L P |
Option award (A) | 29,500 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OLMA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →